France· FR:67904083
GIOTRIF 30 mg, comprimé pelliculé
A medicinal product containing dimaléate d'afatinib, registered in France by BOEHRINGER INGELHEIM INTERNATIONAL, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- DIMALÉATE D'AFATINIB
- Manufacturer
- BOEHRINGER INGELHEIM INTERNATIONAL
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip13340092756570028 plaquette(s) thermoformée(s) PVC PVDC de 1 comprimé(s)EUR 1.58
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dimaléate d'afatinib in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenGIOTRIF 30 mg Filmdragerad tablettBoehringer Ingelheim International GmbH
- SpainGIOTRIF 30 MG COMPRIMIDOS RECUBIERTOS CON PELICULABoehringer Ingelheim International Gmbh
- IrelandGIOTRIF 30 mg film-coated tabletsBoehringer Ingelheim International GmbH
- IcelandGiotrifBoehringer Ingelheim International GmbH*
- NetherlandsGiotrif 30 mg, filmomhulde tablettenBoehringer Ingelheim International GmbH
- NorwayGiotrifBoehringer Ingelheim International GmbH
- PolandGiotrifBoehringer Ingelheim International GmbH
- SwitzerlandGiotrif
Authorised across Europe · EMA
The same active substance is authorised in 8 EEA countries. Names it is sold under:
- Cyprus · Afatinib Afatinib, Afatinib Sapiens
- Greece · Webrix
- Iceland · Giotrif
- Liechtenstein · Giotrif
- Latvia · Afatinib, Afatinib Lotus
- Malta · Afatinib Lotus
- Norway · Giotrif
- Sweden · Afatinib Lotus, Webrix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4e9243e6-94c0-4719-87e4-9fac8d80bced GET /v1/drugs/4e9243e6-94c0-4719-87e4-9fac8d80bced?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67904083",
"date_amm": "2013-09-25",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/13/879",
"substance": "DIMALÉATE D'AFATINIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about dimaléate d'afatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.